Clinical Trials

Prostatic Neoplasms

NCT05155501 2026-04-22

PARTIAL

Phase NA Recruiting

600 enrolled

Prostatic Neoplasms

NCT06172283 2026-04-22

Intermittent Fasting in Prostate Cancer Patients Receiving Androgen Deprivation Therapy

Phase NA Recruiting

30 enrolled

Prostatic Neoplasms

NCT06257264 2026-04-22

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

BreastGastrointestinalGenitourinaryGynecologicThoracic

258 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Ovarian Neoplasms, Prostatic Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06785636 2026-04-22

P300

252 enrolled

BreastDermatologicGastrointestinalGenitourinaryOther hematologic neoplasm

Genital Neoplasms, Male, Neoplasms, Neoplasms by Site, Prostatic Diseases, Prostatic Neoplasms, Urogenital Neoplasms, Male Urogenital Diseases

NCT07328516 2026-04-22

Natural History Study of Early Life Exposures in Agriculture (ELEA)

Enrolling by invitation

64,277 enrolled

Breast Neoplasms, Leukemia, Melanoma, Prostatic Neoplasms, Colorectal Neoplasms

NCT07332455 2026-04-22

First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

54 enrolled

Prostatic Neoplasms

NCT07543757 2026-04-22

PRIME

500 enrolled

Prostatic Neoplasms

NCT07545811 2026-04-22

Study of JANX014 in Subjects With Metastatic Castration-Resistant Prostate Cancer

43 enrolled

Prostatic Neoplasms

NCT00034216 2026-04-21

Collection of Blood From Patients With Cancer

BreastGastrointestinalGenitourinaryThoracic

1,750 enrolled

Breast Neoplasms, Colonic Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Prostatic Neoplasms

NCT02759744 2026-04-21

Fusion Guided Focal Laser Ablation of Prostate Cancer

Phase NA Enrolling by invitation

30 enrolled

Prostatic Neoplasms

NCT04523207 2026-04-21

A Study of Apalutamide (Adjuvant Treatment) and Androgen Deprivation Therapy (ADT) in Participants Who Have Undergone Radical Prostatectomy (RP) for Non-metastatic Prostate Cancer and Who Are at High Risk for Metastases

Phase 2 Completed

108 enrolled 13 charts

Prostatic Neoplasms

NCT04638088 2026-04-21

EMUPRO

2,000 enrolled

Prostatic Neoplasms

NCT04946370 2026-04-21

Phase I/II Trial of Pembrolizumab and Androgen-receptor Inhibitor With or Without 225Ac-J591 for Progressive Metastatic Castration Resistant Prostate Cancer

52 enrolled

Prostatic Neoplasms

NCT06136650 2026-04-21

MK-5684-004

1,314 enrolled

Prostatic Neoplasms

NCT06651632 2026-04-21

WATER IV PCa

Phase NA Recruiting

280 enrolled

Prostatic Neoplasms

NCT06952803 2026-04-21

EvoPAR-PR02

700 enrolled

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT07047118 2026-04-21

A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

138 enrolled

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT07407283 2026-04-21

A Clinical Study of SHR-4394 in Combination With Anti-tumor Therapy in Prostate Cancer

100 enrolled

Prostatic Neoplasms

NCT07541066 2026-04-21

Robotic Telesurgery in Urology

Phase NA Withdrawn

Phase NA Not yet recruiting

Prostatic Neoplasms

NCT07541911 2026-04-21

LaserSAFE

693 enrolled

Phase EARLY_PHASE1 Not yet recruiting

Margins of Excision, Adenocarcinoma, Prostatic Neoplasms

NCT07542379 2026-04-21

The Safety, Dosimetry and Efficacy of 177Lu-FC516 in Patients With Prostate Cancer

13 enrolled

Phase 1 Not yet recruiting

Prostatic Neoplasms

NCT07543055 2026-04-21

A Phase 1 Study of BPX-601 CAR T-Cell Therapy in Adult Participants With Prostate Cancer That Has Returned, is Resistant to Treatment and Has Spread

36 enrolled

Neoplasm Metastasis, Prostatic Neoplasms, Recurrence

NCT00923221 2026-04-20

Collection of Blood From Patients With Prostate Cancer

1,000 enrolled

Prostatic Neoplasms

NCT01834001 2026-04-20

Imaging Studies to Check the Local Response of Prostate Cancer to Radiation Therapy

300 enrolled

Prostatic Neoplasms

NCT03805919 2026-04-20

Men at High Genetic Risk for Prostate Cancer

GastrointestinalGenitourinary

500 enrolled

Colorectal Neoplasms, Hereditary Nonpolyposis, Prostatic Neoplasms

NCT04541030 2026-04-20

Integrated Genomic Prostate Score With MRI Targeted Prostate Biopsies

Active not recruiting

241 enrolled

Prostatic Neoplasms

NCT04706663 2026-04-20

Precision-Based Genomics in Prostate Cancer

2,000 enrolled

Prostatic Neoplasms, Genetic Predisposition to Disease

NCT05800665 2026-04-20

A Study Evaluating the Safety, Pharmacokinetics, and Activity of RO7656594 In Participants With Advanced or Metastatic Prostate Cancer

210 enrolled

Prostatic Neoplasms

NCT05997615 2026-04-20

AMX-500

390 enrolled

Prostatic Neoplasms, Prostatic Neoplasms, Castration-Resistant

NCT06378866 2026-04-20

DIVINE

Phase 2 Recruiting

532 enrolled

Prostatic Neoplasms

NCT06465069 2026-04-20

NEXUS-01

BreastGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

420 enrolled

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Ureteral Neoplasms, Urologic Neoplasms, Triple Negative Breast Neoplasms

NCT06551324 2026-04-20

MEVPRO-1

605 enrolled

Prostatic Neoplasms, Recurrence

NCT06925737 2026-04-20

MK-2400-001

1,440 enrolled

Phase NA Not yet recruiting

Prostatic Neoplasms

NCT07126548 2026-04-20

A Point of Prostate Cancer Diagnosis Virtual Reality Assistant Intervention in Supporting Newly Diagnosed Black Men

200 enrolled

Prostatic Neoplasms

NCT07219147 2026-04-20

177^Lu-PSMA-617 in Combination With Sipuleucel-T for the Treatment of Metastatic Castration-Resistant Prostate Cancer

30 enrolled

Phase 2 Active not recruiting

Prostatic Neoplasms

NCT00951535 2026-04-17

A Prospective Phase II Dose Escalation Study Using IMRT for High Risk N0 M0 Prostate Cancer. ICORG 08-17

251 enrolled

Prostatic Neoplasms

NCT04071236 2026-04-17

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

90 enrolled

Lymphatic Metastasis, Prostatic Neoplasms

NCT05022849 2026-04-17

A Study of JNJ-75229414 for Metastatic Castration-resistant Prostate Cancer Participants

Phase 1 Completed

15 enrolled

Prostatic Neoplasms

NCT05478694 2026-04-17

Outcomes of Focal Ablation for Prostate Cancer

225 enrolled

Prostatic Neoplasms

NCT05766371 2026-04-17

Pembrolizumab Plus 177Lu-PSMA-617 in Patients With Castration Resistant Prostate Cancer

Phase 2 Recruiting

48 enrolled

Prostatic Neoplasms

NCT06315595 2026-04-17

Improvements in Dynamic Contrast-Enhanced MR Angiography and Perfusion and Non-Contrast MRI

1,000 enrolled